BREAKINGVIEWS — China biotech's ingenuity extends to dealmaking
(The author is a Reuters Breakingviews columnist. The opinions expressed are her own.) By Katrina Hamlin HONG KONG, Oct 16 (Reuters Breakingviews) — Chinese drugmakers' 2026 overseas licensing deals just hit $139 bln, beating last year's record. As Big Pharma turns to the country's labs for breakthroughs from cancer to